Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
338.06 K
Value Traded
367.18 K
Short % Float
4.08%
Days to Cover
2.0
-14.69%Week
-31.64%1 Month
-38.57%3 Month
-69.89%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.42 M
EPS (TTM)
-0.54
P/E Ratio
-
Ent. Value
3.41 M
Total Shares
22.33 M
Float Shares
24.34 M
Insiders
2.22%
Institutions
6.51%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
RKTO Catalyst Timeline
Dated clinical, regulatory and corporate events for Rocket One Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rocket One Inc. Common Stock
95Total events
4Upcoming
28Tier-1 (high impact)
2019 to 2030Coverage
Upcoming catalysts 2
Event history 50
▲AcquiredCorporate
Rocket One signs definitive agreement to acquire Tracer Drone Technologies
▲Management ChangeCorporate
Appointment of Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology
▲Partnership / LicenseCorporate
Exclusive license of nanomagnetic AI chip technology from Virginia Commonwealth University
◆Preclinical PoCHT-VAPreclinical
Initial Results from Preclinical Studies
Obesity and Metabolic Healthsource ↗
●IND Enabling CompleteHT-KITPreclinical
Initiate Final Animal Toxicology Studies and Manufacture Clinical Batches
Mast-Cell Derived Cancerssource ↗
◆Full ResultsHT-001Clinical Data
Full Data Set for Open Label PK Cohort
Cutaneous Toxicities associated with EGFR Inhibitorssource ↗
◆Full ResultsHT-001Clinical Data
Full data set for open label PK cohort
Cutaneous Toxicities Associated with EGFR Inhibitorssource ↗
●EU MAA SubmissionHT-001Ex-US Regulatory
Submission to EMA for Clinical Trial Expansion in EU
EGFR Inhibitor Skin Toxicitysource ↗
▲Trial InitiationHT-001Trial
Phase 2a study (CLEER-001) ongoing
EGFR inhibitor induced cutaneous toxicitiessource ↗
▲Primary Endpoint MetHT-001Clinical Data
100% of patients achieved primary efficacy endpoint in Phase 2a
EGFR inhibitor induced cutaneous toxicitiessource ↗
▲Interim AnalysisHT-001Trial
Positive interim data from open-label portion of CLEER-001 Phase 2a trial
pruritus associated with skin toxicities caused by EGFR inhibitorssource ↗
▲Interim AnalysisHT-001Trial
Positive Initial Interim Open Label PK Cohort Data Results
EGFR Inhibitor Skin Toxicitysource ↗
●Manufacturing MilestoneHT-KITCMC / Inspection
GLP animal studies and GMP API manufacturing initiation target
Mast-Cell Derived Cancerssource ↗
▲Partnership / LicenseHT-VACorporate
Obtained License Agreement from Veteran's Affairs for HT-VA
Obesitysource ↗
◆Enrollment UpdateHT-001Trial
All clinical sites active and enrolling in open label and double-blind randomized cohorts
Cutaneous Toxicities Associated with EGFR Inhibitorssource ↗
●Enrollment UpdateHT-001Trial
All Clinical Sites Active and Enrolling in Open Label and Double-Blind Randomized Cohorts
Cutaneous Toxicities associated with EGFR Inhibitorssource ↗
▲Patent GrantedHT-ALZIP / Competition
US Patent Office Awarded HT-ALZ Patent
Alzheimer's Diseasesource ↗
▼Equity OfferingCorporate
Issuance of new warrants exercisable at $1.50 per share, expiring July 3, 2028
●IND Enabling CompleteHT-KITPreclinical
IND-Enabling Animal Toxicology Studies Initiated
Mast-Cell Derived Cancerssource ↗
●Pre IND MeetingHT-KITFDA Meeting
Pre-IND Meeting with FDA and Strategy Confirmed
Mast-Cell Derived Cancerssource ↗
◆Trial InitiationHT-001Trial
HT-001 Phase 2a clinical trial targeted for Q1 2023
Cutaneous Toxicities Associated with EGFR Inhibitorssource ↗
▲First Patient DosedHT-001Trial
Initiated Phase 2a Clinical Trial in Open Label Cohort
Cutaneous Toxicities associated with EGFR Inhibitorssource ↗
▲Enrollment CompleteBioLexaTrial
Open Label dosing portion of Phase 1b Study is completed
Atopic Dermatitissource ↗
▲Trial CompletionBioLexaTrial
Open label dosing portion of Phase 1b study completed
Atopic Dermatitissource ↗
◆Enrollment CompleteTrial
BioLexa Cohort 2 enrollment and dosing expected to conclude Q3 2022
Mild to Moderate Atopic Dermatitissource ↗
◆Interim AnalysisTrial
BioLexa Cohort 2 interim review (n=7) target for May 2022
Mild to Moderate Atopic Dermatitissource ↗
▲Preclinical PoCHT-ALZPreclinical
Proof-of-concept data in Alzheimer's disease mouse model shows significant decrease in amyloid beta
Alzheimer's diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How RKTO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every RKTO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| HT-001 | pruritus associated with skin toxicities caused by EGFR inhibitors | Phase 2a | 2025-04-15 | 50% reduction in pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21Read More | Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 in Open-Label Portion of CLEER HT-001 Phase 2a clinical Trial Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Linsley WayneDirector | Grant/Award | 75,000 75,000 held | $0.00 | 05/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RKTO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RKTO for Q2 2026. | ||||
RKTO Institutional Ownership Trends
RKTO Short Interest
Shares sold short, counted twice a month.
4.08%
Short % of Float
of tradable shares sold short
992.9K
Shares Sold Short
-52.8% vs prior count
2.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
496.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RKTO ranks across every disease it competes in
Competitive Position is a premium feature
See how RKTO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRKTO News
-RKTO
Oct 13, 2026▼ -6.7%on this news
Rocket One Signs Agreement to Advance Nanomagnetic AI Chip Technology and Device Prototyping
Rocket One Inc. has signed an agreement to advance its nanomagnetic AI chip technology and device prototyping. This initiative is part of the SKYMRAM program, which aims to develop next-generation semiconductor memory utilizing spintronics and nanoscale fabrication. The agreement aligns with Rocket One's strategic focus on AI infrastructure, space, and defense computing.
Read more →-RKTO
Oct 6, 2026Rocket One Signs Patent License Agreement with U.S. Air Force for Technology Designed to Capture and Neutralize Hostile Drones
Rocket One Inc. has signed a patent license agreement with the U.S. Air Force to utilize its technology for capturing and neutralizing hostile drones. This agreement is expected to enhance Rocket One's portfolio in counter-unmanned aerial systems (UAS) and expand its applications in defense and critical infrastructure protection. The collaboration signifies a strategic move towards improving security measures.
Read more →-RKTO
Sep 22, 2026Rocket One Signs Definitive Agreement to Acquire Revenue-Generating Tracer Drone Technologies, Accelerating AI and Counter-UAS Expansion Across Public Safety and Defense Markets
Rocket One has signed a definitive agreement to acquire Tracer Drone Technologies, which is expected to enhance its capabilities in AI and counter-UAS technologies. This acquisition aims to bolster Rocket One's presence in public safety and defense markets by adding a revenue-generating platform for drone sales, services, and training. The move could also create new commercial channels for advanced technologies.
Read more →-RKTO
Aug 24, 2026Rocket One Inc. to Attend IDGA’s Counter UAS Summit August 25 – 26, 2026
Rocket One Inc. has announced its participation in the upcoming IDGA's Counter UAS Summit scheduled for August 25-26, 2026. The summit is a key event focused on innovations in counter-drone technology. CEO Robb Knie will represent the company, emphasizing Rocket One's commitment to advancements in defense and technology.
Read more →-RKTO
Aug 18, 2026Rocket One Launches Swarm Stage AI Drone-Swarm Threat Emulation Platform for U.S. Military Counter-UAS
Rocket One Inc. has launched its Swarm Stage AI platform, designed for U.S. military counter-UAS operations. This innovative technology allows for the coordination of thousands of aircraft, enhancing training, testing, and evaluation capabilities for defense organizations. The platform represents a significant advancement in drone-swarm technology.
Read more →-RKTO
Aug 11, 2026Rocket One Accepted into Seagate Partner Program, Expanding AI Infrastructure and Enterprise Data Storage Ecosystem
Rocket One Inc. has been accepted into the Seagate Partner Program, which will enhance its AI infrastructure and enterprise data storage capabilities. This partnership aims to support Rocket One's strategy in AI, space, and defense computing. The collaboration is expected to provide Rocket One with additional resources to advance its technological initiatives.
Read more →-RKTO
Jul 30, 2026Rocket One and NASA Reach Agreement to Advance Space AI Technology
Rocket One Inc. has entered into a licensing agreement with NASA to enhance its AI and space technology portfolio. This partnership will focus on software for spacecraft mission planning, avionics modeling, and engineering workflows. The collaboration aims to serve both commercial and defense applications in the space industry.
Read more →-RKTO
Jul 21, 2026Rocket One Expands AI Infrastructure Platform Through Strategic Partnership with Placeve to Advance Defense, Space, and Intelligent Edge Computing
Rocket One Inc. has announced a strategic partnership with Placeve to enhance its AI infrastructure platform. This collaboration aims to advance technologies in defense, space, and intelligent edge computing. The partnership includes an initial investment and a proposed commercial framework, with Placeve's AI processor technology currently being evaluated through NASA's MISSE program.
Read more →-RKTO
Jul 9, 2026▲ +13.4%on this news
Rocket One Adds SpaceXAI API to Its AI Technology Stack, Advancing Next-Generation Space and Defense Computing
Rocket One Inc. has announced the integration of the SpaceXAI API into its AI technology stack. This addition aims to enhance the company's capabilities in artificial intelligence, defense technologies, and space computing. The move is expected to significantly advance Rocket One's technological offerings in these critical sectors.
Read more →-RKTO
Jun 24, 2026Rocket One Regains Full Nasdaq Compliance with Minimum Bid Price Requirement
Rocket One Inc. has announced that it has regained full compliance with Nasdaq's minimum bid price requirement, following formal notification from the exchange. This compliance matter is now officially closed, allowing the company to continue its operations without listing concerns. Rocket One focuses on next-generation AI computing and defense technologies.
Read more →-RKTO
Jun 22, 2026▼ -6.5%on this news· ran to -19% by day 3shared move
Rocket One Launches Swarm Stage AI(TM) to Counter Autonomous Drone Swarms
Rocket One Inc. has launched its new Swarm Stage AI™ platform designed to counter autonomous drone swarms. This innovative defense technology aims to enhance counter-drone training and protect critical infrastructure and space security. The launch signifies Rocket One's commitment to advancing AI computing and autonomous systems in defense.
Read more →-RKTO
Jun 15, 2026▼ -7.6%on this news
Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets
Rocket One, Inc. reported approximately $8.4 million in cash and cash equivalents. The company outlined its strategic focus on advanced computing technologies, particularly in AI infrastructure and spintronic computing for space and defense markets. This update aims to inform shareholders about the company's financial health and future direction.
Read more →-RKTO
Jun 11, 2026▲ +11.3%on this newsshared move
Rocket One Announces Former NASA Astronaut and International Space Station Commander Shane Kimbrough to Join Rocket One Space Advisory Board
Rocket One has announced the appointment of Shane Kimbrough, a former NASA astronaut and International Space Station commander, to its Space Advisory Board. Kimbrough will provide guidance on space infrastructure, advanced computing, and orbital technology strategy. His extensive experience in the aerospace sector is expected to bolster Rocket One's strategic initiatives.
Read more →-RKTO
Jun 3, 2026ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.) TO SPACE AND DEFENSE ADVISORY BOARD
Rocket One has appointed Major General Malcolm B. Frost (Ret.) to its Space and Defense Advisory Board. With decades of experience in national security and strategic operations, Frost will aid the company's expansion into AI infrastructure for space and defense applications. This move is seen as a strategic enhancement to Rocket One's leadership team.
Read more →-RKTO
Jun 3, 2026Adelina: 4702663 ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.) TO SPACE AND DEFENSE ADVISORY BOARD Former U.S. Army Major General Brings Decades of National Security, Strategic Operations, and Defense Leaders
Rocket One, Inc. has appointed Major General Malcolm B. Frost (Ret.) to its Space and Defense Advisory Board. General Frost brings extensive experience in military operations and strategic planning from his nearly four-decade-long career in the U.S. Army. His appointment is expected to enhance Rocket One's development of advanced computing technologies aimed at addressing national security needs. The company is focused on creating technologies for space and defense applications while navigating significant challenges related to funding and market competition.
Read more →-RKTO
Jun 1, 2026▲ +6.3%on this news· ran to +76% by day 1shared move
Rocket One Appoints Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology
Rocket One Inc. has appointed Dr. Supriyo Bandyopadhyay as Lead Technical Advisor for its AI Nanomagnetic Technology. Dr. Bandyopadhyay, a renowned researcher in nanomagnetics, will oversee the development of the company's innovative AI chip platform, which is designed to be radiation-tolerant and ultra-low-power. This strategic move aims to bolster Rocket One's technological advancements in the field.
Read more →-RKTO
May 28, 2026Rocket One Accepted into AMD AI Developer Program to Advance Simulation of Next-Generation Nanomagnetic AI Accelerator Architecture for AI, Defense and Space Applications
Rocket One Inc. has been accepted into the AMD AI Developer Program, which will aid in the simulation of its next-generation nanomagnetic AI accelerator architecture. This initiative aims to enhance modeling for energy-efficient semiconductor technologies applicable in AI, defense, and space applications. The collaboration is expected to leverage AMD's AI Developer Cloud resources.
Read more →-RKTO
May 28, 2026Rocket One Accepted into AMD AI Developer Program to Advance Simulation of Next-Generation Nanomagnetic AI Accelerator Architecture for Defense and Space Applications
Rocket One Inc. has been accepted into the AMD AI Developer Program, which will provide the company with essential cloud computing resources and technical training aimed at enhancing the development of its nanomagnetic AI accelerator technologies. This partnership is expected to assist Rocket One in evaluating and refining advanced computing architectures pertinent to AI processing performance and energy efficiency. The company is focused on utilizing these resources for future applications in defense and space sectors while recognizing the significant challenges and competition it faces in these rapidly evolving areas.
Read more →-RKTO
May 27, 2026Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing
Hoth Therapeutics has announced its rebranding to Rocket One Inc., effective May 26, 2026, as it shifts its focus to the space economy. The new identity comes alongside an exclusive license for nanomagnetic AI chip technology suited for low-power and radiation-tolerant applications in space and defense. With a new ticker symbol 'RKTO', the company aims to address the evolving needs of the orbital economy and leverage its existing biotechnology pipelining under a subsidiary. Challenges remain, including the early-stage development of technologies and the need for significant capital to advance them.
Read more →About Rocket One Inc. Common Stock
Headquarters720 MONROE STREET, HOBOKEN, NJ, 07030
BIOPHARMAWATCH ELITE PLUS
Trade the next RKTO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime